Navigation Links
Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
Date:7/29/2008

actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; the results of clinical trials; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to upda
'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax to Join Russell 3000 Index
2. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
3. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
4. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
5. Novavax Reports First Quarter 2008 Financial Results
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Opens Its First U.S. Vaccine Plant
8. Novavax CEO to Present at the World Vaccine Congress 2008
9. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
10. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
11. Novavax CEO to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 2015 , ... Brady (NYSE:BRC), a global leader in product ... align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard and the ... of an accurate label, and pictogram uses and meanings. , “With changes to ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ... announces increased partnerships with VA and Military Medical ... Nerve Fiber Density (ENFD) and Sweat Gland Nerve ... fiber neuropathy ( https://therapath.com/skin ). ... Fiber Density (ENFD) on punch skin biopsy is ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: INDV) ... naloxone nasal spray was accepted and received Priority Review ... the treatment of opioid overdose. This naloxone nasal spray ... formulated for optimal absorption into the nasal mucosa. 1 ... training so individuals may be better equipped to help ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company, is pleased to announce that ... injector (RCI-02) have been locked.  Prototypes for industrial ... prepare for an application for CE mark clearance ... in 2016. (Photo: ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... Kits, Water ... Filters and Reusable Bottles, MONROVIA, Calif., Sept. 12 ... the minds of consumers who fear the impact of,bottled water on ... Testing has assembled a family of products on its website, http://www.discovertesting.com, ...
... New Jersey, September 12, Rosetta Genomics Ltd. ... of microRNA-based diagnostics and therapeutics, announced,today the ... present AACR,s,upcoming Molecular Diagnostics in Cancer Therapeutic ... Rosetta Genomics,unique microRNA-based technologies and current development ...
... BARCELONA, Spain, Sept. 12 Elekta is pleased ... planning and,performing Volumetric Intensity Modulated Arc Therapy (VMAT)*. ... featured in the Elekta booth at,this year,s European ... September 8-13, 2007. Performing VMAT with Elekta,enables helical- ...
Cached Biology Technology:Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference 2Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO 2Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO 3
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, ... devices with specialties in single use solutions, headquartered in ... MedConx, Inc. (a California corporation with ... San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility in ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... common, but few studies of lung nodule identification and ... from Kaiser Permanente Southern California identified 7,112 patients who ... within the electronic medical record. Their study ... Association for the Study of Lung Cancer,s (IASLC) ...
... WORCESTER, Mass. A new genetic mutation that causes ... also known as Lou Gehrig,s Disease, has been identified ... the University of Massachusetts Medical School (UMMS). Mutations to ... growth and development of nerve cell axons, is estimated ...
... new study by University of North Carolina School of Medicine ... risk for autism spectrum disorders (ASD) at 12 months received ... In addition, 85 percent of the children found to be ... Year Inventory (FYI), a 63-item questionnaire filled out by their ...
Cached Biology News:UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3Questionnaire completed by parents may help identify 1-year-olds at risk for autism 2
... Our Smart Solutions has now entered ... Screening (HCS) by partnering up with Cellomics, ... from the integration of Beckman Coulter‘s automated ... uncovers deeper biological information at the sub-cellular ...
... in conjunction with the EasyCount System to count ... ViaSure Staining Reagent uses a mixture of ready-to-use ... Bromide to identify live and dead cells, respectively, ... 6 Multi-well Slide provides the ability to ...
... laser scanners is the starting point of ... ,Gene expression analysis, SNP (Single Nucleotide Polymorphism) ... the advancement of research in the post-genomics ... formats and sizes. These arrays call for ...
... This kit allows for rapid, convenient, and ... simple bind/wash/elute process utilizes a spin column ... beads for concentration of proteins which were ... are strong ion exchangers, offering high binding ...
Biology Products: